European Journal of Clinical Pharmacology

, Volume 30, Issue 6, pp 719–722 | Cite as

Serum concentrations and safety of rimantadine in paediatric patients

  • M. C. Nahata
  • M. T. Brady
Originals

Summary

Rimantadine has been shown to be more active in vitro and less toxic than amantadine in adults with influenza A disease. Because of a lack of studies in pediatric patients, we designed a study to evaluate serum concentrations and adverse effects of rimantadine in infants receiving repeated doses. Fourteen hospitalized infants (ages 1–10 months) were given rimantadine syrup at 3 mg/kg/dose in single daily doses during influenza season. Blood samples were obtained prior to dose and at various intervals up to 8 h after doses on the fifth to ninth days of therapy. Adverse effects were assessed based on clinical status, activity level, hematologic and biochemical parameters during 10-day therapy. Steady-state rimantadine peak serum concentration ranged from 100 to 574 ng/ml and time to achieve peak concentration ranged from 2.5 to 6.0 h after the doses. No adverse effects were seen except hematuria in one infant; this patient had the highest rimantadine concentration and longest treatment duration. Hematuria resolved during a follow-up evaluation on the ninth day after stopping therapy. Our data suggest that 1. rimantadine can be given safely at repeated doses of 3 mg/kg/dose in a convenient once-daily regimen; 2. the steady-state peak serum concentrations and time to achieve peak concentration may vary substantially in infants receiving same oral doses; and 3. possible association of adverse effects and high serum concentration or long treatment duration of rimantadine needs further evaluation in small infants.

Key words

rimantadine influenza A adverse effects serum concentration infants 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bryson YJ (1981) Antiviral agents. In: Feigin RD, Cherry JD (eds) Textbook of pediatric infectious diseases. W.B. Saunders, Philadelphia, PAGoogle Scholar
  2. 2.
    Bryson YJ, Monahan C, Pollack M, Shields WD (1980) A prospective double-blind study of side effects associated with the administration of amantadine for influenza A virus prophylaxis. J Infect Dis 141: 543–547Google Scholar
  3. 3.
    Burlington DB, Meiklejohn G, Mostow SR (1982) Anti influenza A virus activity of amantadine hydrochloride and remantadine hydrochloride in ferret tracheal ciliated epithelium. Antimicrob Agents Chemother 21: 794–799Google Scholar
  4. 4.
    Couch RB, Jackson GG (1976) Antiviral agents in influenza summary of influenza workshop VIII. J Infect Dis 134: 516–527Google Scholar
  5. 5.
    Dolin R, Reichman RC, Madore HP et al. (1982) A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med 307: 580–584Google Scholar
  6. 6.
    Douglas RG (1982) Amantadine as an antiviral agent in influenza. N Engl J Med 307: 617–618Google Scholar
  7. 7.
    Hayden FG, Cote KM, Douglas RG Jr (1980) Plaque inhibition assay for drug susceptibility testing of influenza viruses. Antimicrob Agents Chemother 17: 865–870Google Scholar
  8. 8.
    Hayden FG, Hoffman HE, Spyker DA (1983) Differences in side-effects of amantadine hydrochloride and rimantadine hydrochloride related to differences in pharmacokinetics. Antimicrob Agents Chemother 23: 458–464Google Scholar
  9. 9.
    McGahen JW, Neumayer TM, Grunert RR, Hoffman CE (1970) Influenza infections of mice. II. Curative activity of a methyl-1-adamantanemethylamine HCl (rimantadine HCl). Ann NY Acad Sci 173: 557–567Google Scholar
  10. 10.
    Minocha A, Hayden FG, Spyker DA (1985) Pharmacokinetics of amantadine and rimantadine (abstract). Clin Pharmacol Ther 37: 212Google Scholar
  11. 11.
    Schulman JL (1968) Effect of 1-adamantanamine hydrochloride (amantadine HCl) and methyl-1-adamantanemethylamine hydrochloride (rimantadine HCl) on transmission of influenza virus infection in mice. Proc Soc Exp Biol Med 128: 1173–1178Google Scholar
  12. 12.
    Tsunoda A, Maassab HF, Cochran KW, Eveland W (1965) Antiviral activity of α-methyl-1-adamantanemethylamine hydrochloride. In: Antimicrob agents chemother Am Soc Microbiol. Ann Arbor, MI, pp 553–560Google Scholar
  13. 13.
    Van Voris LP, Betts RF, Hayden FG, Christman WA, Douglas RG (1981) Successful treatment of naturally occurring influenza A/USSR/77 H1N1. Am Med Assoc 245: 1128–1131Google Scholar
  14. 14.
    Walker JS, Stephen EL, Spertzel RO (1976) Small particle aerosols of antiviral compounds in treatment of type A influenza pneumonia in mice. J Infect Dis 133 [Suppl]: A140-A144Google Scholar
  15. 15.
    Wingfield WL, Pollack D, Grunert RR (1969) Therapeutic efficacy of amantadine HCl and rimantadine HCl in naturally occurring influenza A2 respiratory illness in man. N Engl J Med 281: 579–584Google Scholar
  16. 16.
    Zlydnikov DM, Kubar OI, Kovaleva TP, Kamforin LE (1981) Study of rimantadine in the USSR: A review of the literature. Rev Infect Dis 3: 408–421Google Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • M. C. Nahata
    • 1
    • 2
  • M. T. Brady
    • 2
  1. 1.College of PharmacyThe Ohio State University, and Children's HospitalColumbusUSA
  2. 2.College of MedicineThe Ohio State University, and Children's HospitalColumbusUSA

Personalised recommendations